Foster & Motley Inc. Reduces Stock Position in Organon & Co. (NYSE:OGN)

Foster & Motley Inc. decreased its holdings in Organon & Co. (NYSE:OGN) by 4.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,699 shares of the company’s stock after selling 1,308 shares during the period. Foster & Motley Inc.’s holdings in Organon & Co. were worth $383,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in OGN. Pacer Advisors Inc. increased its position in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after acquiring an additional 11,140,388 shares during the period. Weiss Asset Management LP bought a new stake in Organon & Co. during the 3rd quarter valued at $32,966,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Organon & Co. by 303.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after buying an additional 934,505 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Organon & Co. by 35.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after buying an additional 875,128 shares in the last quarter. Finally, Philip James Wealth Mangement LLC purchased a new position in shares of Organon & Co. during the third quarter valued at $15,386,000. 77.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $21.33.

Organon & Co. Trading Down 2.4 %

Shares of NYSE:OGN opened at $15.59 on Friday. The company has a market capitalization of $4.01 billion, a PE ratio of 3.09, a P/E/G ratio of 0.89 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The business’s fifty day simple moving average is $15.47 and its 200-day simple moving average is $17.93.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. As a group, equities research analysts predict that Organon & Co. will post 3.83 earnings per share for the current fiscal year.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.